Monographie - Meropenem

Son güncelleme :
18/04/2024

Meropenem

Kimyasal yapı

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Acus	Şili
Amplium	Meksika
Anfletec	Arjantin
Bapentor	Meksika
Biomerem	Venezuela
Klopenem	Arjantin
Mectinex	Şili
Meprim	Şili
Merinfec	Avusturya
Merobac	Ekvador, Kolombiya, Peru
Meromax	Şili
Meronem	Almanya, Belçika, Birleşik Arap Emirlikleri, Büyük Britanya, Danimarka, Ekvador, Finlandiya, Güney Afrika Cumhuriyeti, Hırvatistan, Hollanda, İrlanda, İspanya, İsveç, İsviçre, İzlanda, Kolombiya, Lüksemburg, Macaristan, Norveç, Peru, Polonya, Portekiz, Romanya, Şili, Slovenya, Suudi Arabistan, Tayland, Türkiye, Yunanistan
Meropen	Japonya
Merozan	Yunanistan
Merozem	Arjantin
Merpem	Arjantin
Merrem	Fransa, İtalya, Kanada
Optinem	Avusturya

Kaynaklar : Meropenem

	Tip	Yayın
10	Dergi	Patel PR, Cook SE. Stability of meropenem in intravenous solutions. Am J Health-Syst Pharm 1997 ; 54: 412-421.
266	Dergi	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
1275	Dergi	Walker SE, Varrin S, Yannicelli D, Law S. Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride. Can J Hosp Pharm 1998 ; 51: 156-168.
1415	Dergi	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1454	Dergi	Grant EM, Zhong MK, Ambrose PG, Nicolau DP, Nightingale CH, Quiniliani R. Stability of meropenem in a portable infusion device in a cold pouch. Am J Health-Syst Pharm 2000 ; 57: 992-995.
1508	Dergi	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1639	Dergi	Krämer I. Stability of meropenem in elastomeric portable infusion devices. Eur Hosp Pharm 1997 ; 3: 168-171.
1754	Dergi	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1925	Dergi	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1942	Dergi	Smith DL, Bauer SM, Nicolau DP. Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device. Am J Health-Syst Pharm 2004 ; 61: 1682-1685.
1982	Dergi	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Dergi	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2042	Dergi	Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM. Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2090	Dergi	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Dergi	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2120	Dergi	Mendez A.S.L, Dalomo J, Steppe M; Schapoval E.E.S. Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample. J Pharm Biomed Anal 2006 ; 41: 1363-1366.
2231	Dergi	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	Dergi	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Dergi	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2335	Dergi	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2793	Dergi	Tomasello C, Leggieri A, Cavalli R, Di Perri G, D?Avolio A. In Vitro Stability Evaluation of Different Pharmaceutical Products Containing Meropenem. Hosp Pharm 2015 ; 50, 4 : 296-303.
3012	Dergi	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3112	Dergi	Berthoin K, Le Duff, CS , Marchand-Brynaert J, Carryn S, Tulkens PM Stability of meropenem and doripenem solutions for administration by continuous infusion J Antimicrob Chemother 2010 ; 65: 1073-1075
3152	Dergi	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	Dergi	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3254	Dergi	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	Dergi	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3475	Dergi	Chen L.Y, Chen J, Waters V, Boodhan S. Incompatibility of ciprofloxacin and meropenem injections. Am J Health-Syst Pharm 2013 ;70:1966-1970.
3549	Laboratuar	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3595	Laboratuar	Aciclovir - Summary of Product Characteristics Hospira 2009
3674	Laboratuar	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3767	Dergi	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Dergi	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Afiş	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Afiş	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Afiş	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3837	Dergi	Jaruratanasirikul S, Sriwiriyajan S. Stability of meropenem in normal saline solution after storage at room temperature. South Asian J Trop Med Pub Health 2003 ; 34: 627-629.
3879	Dergi	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3922	Dergi	Wiesholzer, Winter A, Kussmann M, Zeitlinger M, Pichler P, Burgmann H, Reznicek G,Poepp l W. Compatibility of meropenem with different commercial dialysis solutions. Perit Dial Int 2016 doi:10.3747/pdi.2016.0001
3948	Dergi	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
3964	Dergi	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	Dergi	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3997	Dergi	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055	Dergi	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4122	Dergi	Fawaz S, Barton S, Whitney L, Swinden J, Nabhani-Gebara S. Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion. Hosp Pharm 2018 ;54,3:190?196
4145	Dergi	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4147	Dergi	Carlier M, Stove V, Verstraete A.G, De Waele J.J. Stability of generic brands of meropenem reconstituted in isotonic saline. Minerva Anestesiologica 2014 ;81,3:283-287
4180	Dergi	Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wanandy T, Zaidi S, Ming L, Castelino R, Sud K, Peterson G, Patel R. Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions. Perit Dial Int 2018 ;38,6:430-440
4290	Dergi	Venugopalan V, Manigaba K, Borgert S.J, Cope J, Peloquin C.A, Klinker K.P. Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion. Microbiology Insights 2018 ; 11, 1-6
4319	Dergi	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4326	Dergi	Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P. Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion. Pharmazie 2019 ; 74: 357-362.
4380	Laboratuar	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4389	Dergi	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4403	Dergi	De Souza Barbosa F, Capra Pezzi L, Tsao M, Manoela Dias Macedo S, Franco de Oliveira T, Schapoval EES, Mendez ASL. Stability in clinical use and stress testing of meropenem antibiotic by direct infusion ESI-Q-TOF: Quantitative method and identification of degradation products. J Pharm Biomed Anal 2020 ; 179: 112973.
4405	Dergi	Ezquer-Garin C, Ferriols-Lisart R, Martinez-López LM, Sangrador-Pelluz C, Nicolás-Picó J, Alós-Almiñana M. Stability of tedizolid phosphate-sodium rifampicin and tedizolid phosphate-meropenem admixtures in intravenous infusion bags stored at different temperatures Pharmazie 2020 ; 75: 172-176.
4434	Dergi	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	Dergi	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4465	Dergi	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4470	Dergi	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4528	Dergi	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	Dergi	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4572	Dergi	Gostynska A, Piwowarczyk L, Nadolna M, Jelinska A, Dettlaff K, Ogrodowczyk M, Popielarz-Brzezinska M, Stawny M. Toward Safe Pharmacotherapy: The Interplay between Meropenem and Parenteral Nutrition Admixtures. Antibiotics 2021 ; 10, 217.
4592	Dergi	Liebchen U, Rakete S, Vogeser M, Arend F.M, Kinast C, Scharf C, Zoller M, Schönermarck U, Paal M. The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body. Antibiotics 2021 ; 10: 715.
4603	Dergi	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4634	Dergi	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4654	Afiş	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4742	Dergi	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales